Article

In Lupus, Low Vitamin D Means High Renal Disease Risk

There’s a higher risk of total organ damage and end-stage renal disease in patients with SLE.

Low levels of vitamin D are associated with higher rates of end-stage renal disease in patients who have systemic lupus erythematosus (SLE), according to new research findings presented at the 2017 ACR/ARHP Annual Meeting in San Diego.

To clarify the role that vitamin D levels may play in lupus inflammation, researchers at Johns Hopkins University School of Medicine in Baltimore conducted a study to determine how low vitamin D levels could predict later organ damage.

Although lupus can develop in anyone, the condition occurs 9 or 10 times more often in women than in men and is 2 or 3 times more common among women of color, the researchers noted. Vitamin D insufficiency or deficiency is a common problem for patients with SLE, and some evidence suggests that vitamin D replacement therapy may help improve renal disease activity, they added.

The investigators analyzed data on 1392 patients with SLE, including their first medical office visit during which vitamin D levels were measured, and then their organ or tissue damage on all of the patients’ follow-up clinic visits.

The patients were 92% female, had a mean age of 47.3 years, and were 50% Caucasian and 41% African-American. They were categorized based on 25-hydroxy vitamin D levels that were below 20 ng/mL or at or above 20 ng/mL on their first office visit. At their first office visit in which vitamin D levels were measured, 27.3% had levels below 20 ng/mL.

The researchers then calculated the risk of lifetime organ damage for patients who had low vitamin D levels using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index scoring system. Organ damage rates were adjusted for age, gender, and ethnicity.

“We have shown that supplementing vitamin D reduces urine protein, which is the best predictor of future renal failure,” said Michelle A. Petri, MD, PhD, Director, Hopkins Lupus Center and a lead author.

The relative risk (RR) of renal damage was the highest for patients with SLE whose vitamin D levels were insufficient (RR, 1.87; 1.66 adjusted). Skin damage was another concern, with an RR of 1.69 (1.22 adjusted). Total organ damage RR was 1.11 (1.17 adjusted).

Other measured long-term outcomes included ocular, neuropsychiatric, pulmonary, cardiovascular, GI, and musculoskeletal, but the RR of damage to these organ systems was not significant. There was no association between low vitamin D and musculoskeletal damage, including osteoporotic fractures.

The researchers concluded that low vitamin D is associated with a higher risk of total organ damage and with end-stage renal disease for patients with lupus.

“Supplementary vitamin D is very safe,” said Dr Petri. “It helps to prevent one of the most dreaded complications of SLE, and likely has a role in preventing blood clots and cardiovascular disease as well. Vitamin D supplementation, which can reduce proteinuria, should be a part of the treatment plan for lupus nephritis patients.”

Disclosures:

This research was supported by funding from the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.